Tofacitinib for Hospitalized Acute Severe Ulcerative Colitis Management

Sponsor
McMaster University
Study ID
NCT04925973
Phase
PHASE2
Status
Active Not Recruiting

Conditions

  • Ulcerative Colitis Acute

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The TRIUMPH study was designed to build on the existing literature by studying the efficacy of tofacitinib in hospitalized patients with acute severe ulcerative colitis. This trial will provide evidence for a possible new indication for the use of tofacitinib.

Key Dates

Start date
Jun 1, 2021
Status verified
Oct 2023
Primary completion
Dec 31, 2023
Completion
Dec 31, 2023

Study Design

Enrollment
24 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment arm
    Tofacitinib 10mg PO BID

Primary Outcome Measure

Clinical response at day 7 [ Time Frame: 7 days ]

Related Studies